Relapse-free survial and target identification to enhance response with neoadjuvant and adjuvant dabrafenib + trametinib (D+T) treatment compared to standard-of-care (SOC) surgery in patients (pts) with high-risk resectable BRAF-mutant metastatic melanoma.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jennifer Ann Wargo, Rodabe Navroze Amaria, Peter A. Prieto, Miles Cameron Andrews, Michael T. Tetzlaff, Phillip Andrew Futreal, Patrick Hwu, Wen-Jen Hwu, Isabella Claudia Glitza, Hussein Abdul-Hassan Tawbi, Janice N. Cormier, Jeffrey Edwin Lee, Sapna Pradyuman Patel, Lauren Simpson, Elizabeth M. Burton, Roland L. Bassett, Merrick I. Ross, Jeffrey E. Gershenwald, Michael A. Davies, Scott Eric Woodman
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2891655668